Related Experiment Video
Updated: Jun 24, 2026
The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
Pediatric multiple sclerosis
Emmanuelle Waubant1, Dorothee Chabas
1Emmanuelle Waubant, MD, PhD University of California San Francisco, Regional Pediatric Multiple Sclerosis Center, 350 Parnassus Avenue, Suite 908, San Francisco, CA 94117, USA. emmanuelle.waubant@ucsf.edu.
Insights
Diagnosing pediatric multiple sclerosis (MS) is difficult due to unique early symptoms and imaging findings. Current treatments for adults are used off-label, with some children requiring second-line therapies.
Area of Science:
- Pediatric Neurology
- Neuroimmunology
- Clinical Diagnosis
Background:
- Pediatric multiple sclerosis (MS) diagnosis presents unique challenges compared to adult-onset MS.
- Limited diagnostic criteria and overlap with acute disseminated encephalomyelitis complicate early identification.
- Early age of onset is associated with distinct clinical and radiological features.
Purpose of the Study:
- To highlight the diagnostic challenges in pediatric MS.
- To describe specific features of early-onset MS in children.
- To discuss therapeutic considerations for pediatric MS.
Main Methods:
- Review of clinical presentation in pediatric MS.
- Analysis of neuroimaging findings (MRI) in young patients.
- Evaluation of cerebrospinal fluid (CSF) biomarkers.
- Assessment of treatment responses to adult-approved MS therapies.
Main Results:
- Pediatric MS often presents with encephalopathy, seizures, and brainstem/cerebellar symptoms.
- Initial MRI may show posterior fossa involvement and transient T2-bright lesions.
- CSF analysis may lack oligoclonal bands or elevated IgG index in children.
- Some children experience disease breakthrough on first-line adult therapies.
Conclusions:
- Pediatric MS diagnosis requires careful consideration of specific early-onset features.
- Current therapeutic strategies involve off-label use of adult MS drugs.
- Second-line therapies may be necessary for children with treatment-resistant pediatric MS.
Abstract:
The diagnosis of multiple sclerosis (MS) in a child remains challenging, given the limited diagnostic criteria and the somewhat poorly defined overlap with acute disseminated encephalomyelitis. Although there are many similarities between pediatric-onset and adult-onset MS, an earlier age at disease presentation seems to be associated with specific features such as more frequent encephalopathy, seizures, and brainstem and cerebellar symptoms during the first event. In addition, the initial brain MRI scan of younger patients shows more frequent involvement of the posterior fossa and higher numbers of ovoid, ill-defined T2-bright foci that often partially resolve on the follow-up scan, thereby challenging early diagnosis. Finally, the spinal fluid in younger patients may fail to reveal oligoclonal bands or elevated IgG index at disease onset. No therapy for MS in children has been approved by the US Food and Drug Administration. As a result, physicians have started to use off-label drugs approved for adults. Recent data suggest that some children experience a disease breakthrough on first-line therapies approved for adult MS, and thus second-line therapies must be considered.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism